Search results
Showing 301 to 315 of 2106 results for technology appraisal
NICE is unable to make a recommendation on concizumab (Alhemo) for treating haemophilia A or B in people 12 years and over with factor inhibitors. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1124
Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) (TA1137)
NICE is unable to make a recommendation on canagliflozin (Invokana) for treating type 2 diabetes in children and young people 10 to 17 years. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1137
NICE is unable to make a recommendation about the use in the NHS of ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation because no evidence submission was received from Janssen–Cilag.
Show all sections
Sections for TA452
NICE is unable to make a recommendation on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy. This is because AstraZeneca did not provide an evidence submission.
Show all sections
Sections for TA750
NICE is unable to make a recommendation on slow-release potassium bicarbonate–potassium citrate (Sibnayal) for treating distal renal tubular acidosis in people 1 year and over. This is because Advicenne withdrew its evidence submission.
Show all sections
Sections for TA838
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)
NICE is unable to make a recommendation about the use in the NHS of abatacept (Orencia) for treating psoriatic arthritis after DMARDs. This is because Bristol–Myers Squibb Pharmaceuticals Ltd did not provide an evidence submission.
Show all sections
Sections for TA568
NICE is unable to make a recommendation on atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer. This is because Roche did not provide an evidence submission.
Show all sections
Sections for TA618
NICE is unable to make a recommendation on sarilumab (Kevzara) for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1104
NICE is unable to make a recommendation on cemiplimab (Libtayo) for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer in adults. This is because Sanofi did not provide an evidence submission.
Show all sections
Sections for TA848
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) (TA1006)
NICE is unable to make a recommendation about the use in the NHS of empagliflozin (Jardiance) for treating type 2 diabetes in people aged 10 to 17 years. This is because Boehringer Ingelheim did not provide an evidence submission.
Show all sections
Sections for TA1006
NICE is unable to make a recommendation on treosulfan (Trecondi) with fludarabine before allogeneic stem cell transplant for babies, children and young people aged 1 month to 17 years with non-malignant diseases. This is because Medac Pharma did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA945
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults.
NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous anti-HER2-based regimen in adults. This is because Daiichi Sankyo UK did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA879
NICE is unable to make a recommendation about the use in the NHS of enzalutamide (Xtandi) for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy. This is because Astellas Pharma did not provide an evidence submission.
Show all sections
Sections for TA994
NICE is unable to make a recommendation on subcutaneous spesolimab (Spevigo) 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1144